
Peking University First Hospital has a total capacity of 1,805 beds across three campuses: Central, Miyun, and Daxing. The hospital delivers a full range of inpatient and outpatient services, serving patients across China and internationally.
Established in 1915, Peking University First Hospital (PUFH) is one of China's most prestigious medical institutions, affiliated with the Peking University Health Science Center. As a top-tier tertiary hospital classified as Grade 3A, it is recognized for its leadership in clinical excellence, education, and research. Over the decades, PUFH has been pioneering in shaping modern Chinese medicine, particularly in specialties such as urology, nephrology, pediatrics, neurology, cardiology, and organ transplantation.
The hospital is home to a team of highly qualified doctors and professors, including many national-level experts. Known for managing complex and rare diseases, it continues to advance patient care through innovation, multidisciplinary collaboration, and compassionate treatment.
Advanced Technology & Facilities
Key Services at Peking University First Hospital
Peking University First Hospital blends a century of medical heritage with high-quality clinical care, innovative research, and comprehensive education. It stands as a benchmark of excellence in China, committed to improving patient outcomes through multidisciplinary collaboration and compassionate, personalized care.

The hospital has approximately 50 inpatient beds in its main campus, along with nine satellite clinics across Beijing. It manages over 2,500 outpatient visits each week and provides care to hundreds of thousands of patients annually, both local and international.
Beijing United Family Hospital (BJU) is one of China’s most prestigious private medical institutions, known for delivering world-class healthcare that meets international standards. Established in 1997, it was the first foreign-invested hospital in China and has since become a trusted choice for both International and Chinese patients seeking high-quality, patient-focused care. As part of the United Family Healthcare network, BJU has built a reputation for medical excellence, advanced technology, and a uniquely personalized approach to treatment.
The hospital is staffed by a diverse team of internationally trained doctors, many of whom have practiced in top healthcare systems across the U.S., Europe, and Asia. This global expertise is complemented by the latest medical equipment, multilingual support services, and a strong commitment to clinical safety and patient satisfaction. Recognized by the Joint Commission International (JCI) for meeting the highest standards in healthcare delivery, BJU offers a full spectrum of medical services across numerous specialties, including family medicine, internal medicine, orthopedics, oncology, cardiology, obstetrics, pediatrics, and plastic surgery.
Advanced Technology & Facilities
Key Services at BJU
Beijing United Family Hospital stands as a pioneer in international-standard healthcare in China, blending modern technology, world-class medical expertise, and a warm, comprehensive approach to family health.

As part of Singapore‑listed Raffles Medical Group, founded in 1976, RMG China operates 5 tertiary hospitals and over 100 clinics, supported by 430+ physicians and 900+ nurses & allied health professionals, delivering comprehensive inpatient and outpatient services.
Raffles Medical Group has operated in China since 2010, growing into a trusted name among both local and expatriate communities. All RMG China hospitals and clinics follow the Group’s Institutional Group Practice Model, which emphasizes integrated, peer-reviewed, and clinically audited care. Backed by Raffles Hospital Singapore, accredited by Joint Commission International (JCI), the network ensures alignment with global standards for quality and patient safety. With a rigorous clinical governance framework, strategic insurance and corporate partnerships, and a presence in key Chinese cities, RMG serves over 2.8 million patients annually. The Group continues to expand across China, offering world-class healthcare that combines international expertise with localized, patient-centered care.
Advanced Technology & Facilities
Key Services at Raffles Medical Group China
Raffles Medical Group China is a leading integrated private hospital network, delivering high-quality, multidisciplinary medical care in major Chinese cities. With its robust institutional infrastructure, advanced diagnostic and treatment facilities, and a reputation anchored by the Singapore-based Raffles Hospital, RMG China continues to expand and uphold global healthcare standards.

GoBroad Healthcare Group, founded in 2017, is a leading medical network in China, specializing in the treatment of complex hematologic diseases and solid tumors. The group integrates clinical treatment, research, reference laboratories, and medical information technology under an Academic Research Organization model. With seven hospitals across Beijing, Shanghai, and Guangzhou, it provides advanced therapies including CAR-T cell therapy, hematopoietic stem cell transplantation, chemotherapy, radiotherapy, and targeted therapy. Its multidisciplinary teams ensure that patients receive comprehensive and personalized treatment for both common and rare conditions. The group is known for its patient-centered approach by combining modern medical science with innovative therapies and long-term follow-up care. With international collaborations, multilingual staff, and dedicated global patient services, it has become a trusted choice for individuals seeking specialized cancer and hematology treatments in China. By focusing on research-driven medicine, advanced facilities, and supportive care, GoBroad Healthcare Group continues to enhance patient survival, recovery, and long-term quality of life.
Advanced Technology & Facilities
Key Services



China has become an established location for CAR T-cell therapy due to strong academic medicine, expanding clinical experience, and dedicated cellular immunotherapy centers. Many clinics operate within hospital based environments that support advanced laboratory services, intensive care access, and structured safety pathways. Patient evaluation is a key first step and usually includes confirmation of diagnosis, review of previous treatments, infection screening, and organ function assessment. This process helps clinics determine whether a patient is an appropriate candidate for CAR T-cell therapy.
The cost of CAR T-cell therapy in China typically ranges between USD 100,000 and USD 320,000. Final costs can vary based on cancer type, the CAR T product selected, hospital level, length of inpatient care, and the degree of monitoring required. Recovery is often milestone based. The first week usually involves inpatient observation, the first month focuses on immune recovery and side effect management, and patients may return to regular routines over the following months. Not every patient is an ideal candidate, so each case requires individual assessment and a tailored treatment plan by the clinic team.
This information is for educational purposes and does not replace an in person consultation with a qualified specialist.
CAR T-cell therapy clinics in China generally follow structured care pathways supported by multidisciplinary teams. These clinics emphasize clean facilities, coordinated workflows, and safety protocols designed to manage immune related risks. Many centers also provide support services for patients traveling from other regions or countries.
Beijing Gobroad Boren Hospital Cellular Immunotherapy Center in Beijing is widely known for its focus on blood cancers such as leukemia and lymphoma. The center delivers the full CAR T-cell therapy process, including patient screening, cell collection, infusion, and close monitoring for complications like cytokine release syndrome. Its experience with both clinical trials and approved CAR T products supports a structured and safety focused approach.
Shanghai SinoUnited Hospital International CAR T Cell Therapy Center in Shanghai is designed to serve both local and international patients. The center emphasizes streamlined coordination of cell manufacturing, inpatient care, and post treatment monitoring. Multidisciplinary collaboration and clear patient communication are central to its treatment model.
Jiahui International Cancer Center CAR T Therapy Program in Shanghai offers integrated care through teams of hematologists, oncologists, and intensive care specialists. The program focuses on personalized treatment planning, international standard clinical practices, and long term follow up, which can be valuable for patients with complex or relapsed disease.
Best Clinic Abroad supports international patients who are considering CAR T-cell therapy in China. The team helps connect you with verified clinics, clarify your options, and coordinate key details around your treatment stay.
➤ Initial virtual consultation - Arrange an online review of medical records so clinics can provide preliminary feedback on eligibility.
➤ Clear package information - Request transparent cost estimates that outline typical inclusions such as hospital care, laboratory services, and follow up.
If you are exploring CAR T-cell therapy in China, you can start by sharing your case with Best Clinic Abroad and receive guided support in choosing a suitable clinic and planning your next steps.
Question: What risks are associated with CAR T-cell therapy
Answer: CAR T-cell therapy can cause immune related side effects such as cytokine release syndrome or neurologic symptoms. Clinics manage these risks through close monitoring and established safety protocols.
Question: How long do patients usually remain under follow up after treatment
Answer: Follow up often continues for several months with regular clinic visits and blood tests to monitor immune recovery and detect delayed side effects.